Sanofi looks to trim down with divestments

05:51 EDT 16 Apr 2018 | Pharmafile

Sanofi has begun part of a larger process of slimming down its business with the sales of 12 medicines.

It offloaded the drugs to Charterhouse Capital Partner’s Cooper-Vemedia for €158 million, with the products ranging across dermatology, eye-care and antiseptics.

The products are considered to be non-core products for Sanofi, mainly selling in France and Italy.

Sanofi revealed that it would be divesting of the assets and the sites currently manufacturing them would remain in its hands.

read more

Original Article: Sanofi looks to trim down with divestments


More From BioPortfolio on "Sanofi looks to trim down with divestments"

Quick Search


Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...